STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRY
  4. [SCHEDULE 13D/A] ARS Pharmaceuticals, Inc. SEC Filing

[SCHEDULE 13D/A] ARS Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SPRY logo
ARS Pharms

NASDAQ:SPRY

SPRY Rankings

#3156 Ranked by Market Cap
N/A Ranked by Dividends

SPRY Latest News

Jul 18, 2025
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
May 27, 2025
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
May 14, 2025
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
May 7, 2025
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
May 5, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

SPRY Latest SEC Filings

Jul 3, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity
Jul 2, 2025
[SCHEDULE 13D/A] ARS Pharmaceuticals, Inc. SEC Filing
Jul 1, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity
Jul 1, 2025
[144] ARS Pharmaceuticals, Inc. SEC Filing
Jun 27, 2025
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity

SPRY Stock Data

1.72B
73.16M
23.19%
75.88%
19.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO